Multi-drug-resistant Gram-negative bacteria pneumonia patients
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: ICU patients in seven tertiary A hospitals in Shandong Province who received intravenous administration combined with nebulized colistin or ceftazidime/avibactam from January 1, 2018, to July 31, 2025. 1. Patients with microbiologically confirmed MDR-GNB pneumonia. 2. Patients with an artificial airway. 3. Age >= 18 years.
Exclusion criteria
Exclusion criteria: 1.In vitro drug sensitivity tests showed that MDR-GNB was resistant to colistin or ceftazidime/avibactam, such as pan - drug resistant Acinetobacter baumannii, metallo - enzyme - producing CRO, Serratia marcescens, Proteus spp., Morganella spp., Burkholderia cepacia, etc. 2.Severe multiple organ failure, with an APACHE II score >=40 at enrollment. 3.Patients who had been treated with intravenous or nebulized polymyxins or ceftazidime/avibactam or polymyxins combined with ceftazidime/avibactam within 7 days before enrollment. 4.Acquired immune deficiency syndrome and human immunodeficiency virus carriers. 5.Patients with missing data more than 20%.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All-cause mortality at 30 day; | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients with clinical response at 7 day;All-cause mortality at 14 day;Proportion of patients with clinical response at 14 day;14-Day clearance of MDR-GNB microorganisms;Incidence of acute kidney injury;Incidence of airway spasm during aerosolized colistin;Days in ICU;Total hospital length;Days on mechanical ventilation within 30 days;Days with RRT within 30 days;Days of vasopressors within 30 days;Days of antibiotics-free within 30 days; | — |
Countries
China
Contacts
Shandong Provincial Hospital Affiliated to Shandong First Medical University